NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab for Women With Breast Cancer
Status:
Unknown status
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
This is a prospective, single-arm, phase II study of 32 evaluable patients treated with
NEOADjuvant Aromatase inhibitor and Pertuzumab/Trastuzumab (NEOADAPT) without chemotherapy
for hormone receptor positive (HR+), [i.e. Estrogen Receptor positive (ER+) and/or
Progesterone Receptor positive (PR+)] HER2+ localized, non-metastatic stage I - IIb breast
cancer.